A peer-reviewed validation study found that patients with high OncoPrism-NSCLC scores had a 71% response rate to checkpoint inhibitor-based treatment, compared with 36% in lower-scoring groups. The analysis included 1,487 patients across four datasets, although the prospective clinical utility of using the test to choose treatment remains unproven.
Seres Therapeutics Inc. (Nasdaq: MCRB) has reported early clinical data for SER-155 in immune checkpoint inhibitor-related enterocolitis, a gastrointestinal immune-related adverse event that can interrupt cancer immunotherapy. The investigator-sponsored study evaluated the live biotherapeutic in 15 patients with moderate to severe disease and showed an immunosuppressive free clinical response in 80 percent of participants at
Read how Samsung Bioepis SB27’s positive Phase 1 and Phase 3 data could reshape the Keytruda biosimilar race and oncology access.
Discover how CytoDyn Inc.’s leronlimab data could reshape TNBC immunotherapy and expand checkpoint treatment potential.
Kazia Therapeutics Limited has presented new clinical and translational data at the 2025 San Antonio Breast Cancer Symposium demonstrating that paxalisib, its investigational brain-penetrant PI3K/mTOR inhibitor, may suppress circulating tumor cell clusters and reverse immune exhaustion in two of the most treatment-resistant breast cancer subtypes—HER2-positive metastatic breast cancer and triple-negative breast cancer. The early evidence,